Martínez-Feito A, et al. - In patients with rheumatoid arthritis (RA), experts gauged the impact of concomitant use of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) with adalimumab or infliximab on maintaining serum drug and clinical outcomes after the first year of treatment. They also assessed how methotrexate (MTX) dose impacts these outcomes. In patients having RA treated with infliximab or adalimumab, they noted the persistence of serum tumor necrosis factor inhibitor (TNFi) and the likelihood of attaining clinical response are impacted by MTX, but not by other csDMARDs. Compared to patients without MTX, the likelihood of sustaining serum TNFi levels was doubled in TNFi+MTX patients. Nonetheless, only for the highest MTX dose, they observed statistically significant results.